Carlsmed (NASDAQ:CARL) COO Sells $10,749.33 in Stock

Carlsmed, Inc. (NASDAQ:CARL) COO Jeffrey Bertolini sold 747 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $14.39, for a total value of $10,749.33. Following the completion of the transaction, the chief operating officer directly owned 22,489 shares in the company, valued at $323,616.71. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jeffrey Bertolini also recently made the following trade(s):

• On Wednesday, September 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The stock was sold at an average price of $13.99, for a total value of $3,399.57.

Carlsmed Price Performance

Shares of NASDAQ CARL opened at $14.05 on Friday. Carlsmed, Inc. has a 52 week low of $8.50 and a 52 week high of $17.23. The business’s 50 day moving average price is $14.89 and its 200 day moving average price is $12.22. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18. The firm has a market cap of $383.56 million, a P/E ratio of -9.83 and a beta of 2.09.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01. The business had revenue of $18.94 million during the quarter. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. On average, sell-side analysts expect that Carlsmed, Inc. will post -1.5 earnings per share for the current year.

Institutional Investors Weigh In On Carlsmed

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Zevenbergen Capital Investments LLC lifted its holdings in Carlsmed by 50.4% during the third quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock valued at $252,000 after purchasing an additional 6,000 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Carlsmed during the second quarter worth about $108,000. Jupiter Topco LLC acquired a new position in shares of Carlsmed during the 2nd quarter worth about $12,992,000. Parkman Healthcare Partners LLC purchased a new position in Carlsmed in the 2nd quarter valued at about $6,200,000. Finally, Alpine Woods Capital Investors LLC purchased a new position in Carlsmed in the 2nd quarter valued at about $161,000.

Analyst Ratings Changes

Several equities research analysts have weighed in on CARL shares. Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings raised Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Truist Financial raised their target price on Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. BTIG Research reiterated a “buy” rating and set a $23.00 price target on shares of Carlsmed in a research report on Monday, September 28th. Finally, Needham & Company LLC initiated coverage on Carlsmed in a report on Wednesday, July 1st. They issued a “buy” rating and a $17.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.25.

About Carlsmed

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company develops patient-specific implants and digital planning tools intended to help surgeons address spinal deformity and degenerative conditions with procedures tailored to an individual patient’s anatomy and surgical goals.

Its principal products are offered under the aprevo brand and include personalized interbody fusion implants produced using three-dimensional printing, along with software that supports implant design and preoperative planning.